Barinthus Biotherapeutics: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Barinthus Biotherapeutics (NASDAQ:BRNS) reported Q4 earnings, beating estimates with an EPS of $-0.45 against an expected $-0.5. However, revenue decreased by $6.46 million compared to the same period last year. Despite beating EPS estimates last quarter, the company's share price dropped by 7% the following day.
March 20, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Barinthus Biotherapeutics reported better than expected Q4 EPS but saw a significant revenue drop compared to last year. Previous quarter's EPS beat resulted in a share price drop.
Despite beating EPS estimates, the significant revenue drop and historical context of a share price decline following last quarter's EPS beat suggest a potential short-term negative impact on BRNS's stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100